Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 352

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 352
---
ortization of Intangible Asset

Amortization of intangible asset was $7,317 for the three months ended June 30, 2025 and 2024. This amortization is related to the technology acquired for the BioArkive acquisition completed in December 2021.

Other Income (Expense)

Interest income decreased by approximately $0.5 million for the three months ended June 30, 2025 as compared to the three months ended June 30, 2024, driven primarily by lower interest rates and a lower total cash balance.

There was no other income for the three months ended June 30, 2025, compared to $8 thousand for the three months ended June 30, 2024. This was primarily a result of there being no marketable securities as of June 30, 2025 and December 31, 2024, respectively.

Comparison of the Six Months Ended June 30, 2025 and 2024

The following table summarizes our results of operations for the periods indicated:

29

Six Months Ended June 30,Change20252024$%(in thousands, except percentages)Operating expensesResearch and development$21,926$21,854$720.3%General and administrative8,3028,370(68)(0.8)%  Amortization of intangible asset1515——%Total operating expenses30,24330,2394—%Loss from operations(30,243)(30,239)(4)—%Other income (expense)Interest income7631,631(868)(53.2)%Other income— 221 (221)(100.0)%Net loss$(29,480)$(28,387)$(1,093)3.9 %

Research and Development

The following table summarizes the components of research and development expenses for the periods indicated:

Six Months Ended June 30,Change20252024$%(in thousands, except percentages)Direct research and development expenses by program:atebimetinib (IMM-1-104)$9,427 $7,454 $1,973 26.5 %IMM-6-4151,902 2,160 (258)(11.9)%Other programs2,420 3,536 (1,116)(31.6)%Indirect research and development expenses:Employee-related costs6,053 6,687 (634)(9.5)%Stock-based compensation expense1,343